Immunoassay Developed for Quantitative Detection of Serum Interleukin‐6
|
By LabMedica International staff writers Posted on 07 Apr 2021 |

Image: The quantum dot (QD)‐based fluorescence lateral flow immunoassay (LFIA) strip can rapidly and accurately detect IL‐6 levels at different concentrations (Photo courtesy of University of South China)
Interleukin‐6 (IL‐6) is a multifunctional protein and is primarily produced by macrophages, monocytes, fibroblasts, and T lymphocytes, and plays important roles in immune regulation, hematopoiesis, inflammation, and tumorigenesis.
IL‐6 has shown the highest value in the diagnosis of sepsis compared with procalcitonin (PCT) and C‐reactive protein (CRP), which are also important biomarkers of infection. Traditional IL‐6 detection methods include chemiluminescence immunoassays (CLIA), enzyme‐linked immunosorbent assays (ELISA) and electrochemiluminescence immunoassays (ECLIA).
Medical Scientists at the Second Affiliated Hospital of University of South China (Hengyang, China) developed a quantum dot (QD)‐based fluorescence lateral flow immunoassay (LFIA) strip that can rapidly and accurately detect IL‐6 levels. The QD‐based LFIA strips were fabricated by conjugating cadmium selenide/zinc sulfide (CdSe/ZnS) QDs to the IL‐6 antibody. The strips were made of nitrocellulose (NC) membranes, semi‐rigid polyvinylchloride (PVC) sheets, and polyester fiber. The IL‐6 CLIA kits were from Beckman Coulter (Pasadena, CA, USA).
The fluorescence intensity of the test (T) line and the control (C) line on the strip were detected using the self‐designed KF‐Q001‐A fluorescence immunoassay analyzer (Kingfocus Biomedical Engineering Co., Ltd, Shenzhen City, China). The QDs and antibodies were dispensed onto the strip using a piece of three‐dimensional gold‐spraying equipment. IL‐6 CLIA detection was performed on the Beckman Coulter Dxl800 instrument. A total of 200 human serum samples were obtained from a local hospital, The IL‐6 concentrations of these samples ranged from 0 to 580.42 ng/mL. The samples were detected using the strip and the Beckman IL‐6 CLIA kit within two hours of each other.
The investigators reported that the test strip's linear range was 10–4,000 pg/mL, with a linear correlation coefficient of R2 ≥ 0.959. The sensitivity of the test strip was 1.995 pg/mL. The recovery rate was 95.72%–102.63%, indicating satisfying accuracy. The coefficient of variation (CV) of the intra‐assay was 2.148%–3.903%, while the inter‐assay was 2.412%–5.293%, verifying the strip's high precision. The cross‐reaction rates with various interleukins (IL‐1α, IL‐1β, IL‐2, IL‐4, and IL‐8) and interferon‐γ (IFN‐γ) were all less than 0.1%.
The authors concluded that they had successfully established a QD‐based LFIA method for rapid and accurate detection of human serum IL‐6, providing a more simple, robust, and economic point-of-care technology (POCT) for IL‐6 quantification, which is of great value for the early detection and treatment of sepsis and related disorders. The study was published on March 24, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Second Affiliated Hospital of University of South China
Beckman Coulter
Kingfocus Biomedical Engineering Co., Ltd
IL‐6 has shown the highest value in the diagnosis of sepsis compared with procalcitonin (PCT) and C‐reactive protein (CRP), which are also important biomarkers of infection. Traditional IL‐6 detection methods include chemiluminescence immunoassays (CLIA), enzyme‐linked immunosorbent assays (ELISA) and electrochemiluminescence immunoassays (ECLIA).
Medical Scientists at the Second Affiliated Hospital of University of South China (Hengyang, China) developed a quantum dot (QD)‐based fluorescence lateral flow immunoassay (LFIA) strip that can rapidly and accurately detect IL‐6 levels. The QD‐based LFIA strips were fabricated by conjugating cadmium selenide/zinc sulfide (CdSe/ZnS) QDs to the IL‐6 antibody. The strips were made of nitrocellulose (NC) membranes, semi‐rigid polyvinylchloride (PVC) sheets, and polyester fiber. The IL‐6 CLIA kits were from Beckman Coulter (Pasadena, CA, USA).
The fluorescence intensity of the test (T) line and the control (C) line on the strip were detected using the self‐designed KF‐Q001‐A fluorescence immunoassay analyzer (Kingfocus Biomedical Engineering Co., Ltd, Shenzhen City, China). The QDs and antibodies were dispensed onto the strip using a piece of three‐dimensional gold‐spraying equipment. IL‐6 CLIA detection was performed on the Beckman Coulter Dxl800 instrument. A total of 200 human serum samples were obtained from a local hospital, The IL‐6 concentrations of these samples ranged from 0 to 580.42 ng/mL. The samples were detected using the strip and the Beckman IL‐6 CLIA kit within two hours of each other.
The investigators reported that the test strip's linear range was 10–4,000 pg/mL, with a linear correlation coefficient of R2 ≥ 0.959. The sensitivity of the test strip was 1.995 pg/mL. The recovery rate was 95.72%–102.63%, indicating satisfying accuracy. The coefficient of variation (CV) of the intra‐assay was 2.148%–3.903%, while the inter‐assay was 2.412%–5.293%, verifying the strip's high precision. The cross‐reaction rates with various interleukins (IL‐1α, IL‐1β, IL‐2, IL‐4, and IL‐8) and interferon‐γ (IFN‐γ) were all less than 0.1%.
The authors concluded that they had successfully established a QD‐based LFIA method for rapid and accurate detection of human serum IL‐6, providing a more simple, robust, and economic point-of-care technology (POCT) for IL‐6 quantification, which is of great value for the early detection and treatment of sepsis and related disorders. The study was published on March 24, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Second Affiliated Hospital of University of South China
Beckman Coulter
Kingfocus Biomedical Engineering Co., Ltd
Latest Immunology News
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more
Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak.... Read more
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more
Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more








